Eniola should re-apply positioning the venture as the natural addition to Heartfelt's Life Sciences AI cluster alongside Kiin Bio and TriasBio — not as a biotech grant applicant. The one-sentence description on the form should lead with the structural moat: 'The only drug resistance mutation predictor that works from protein sequence alone — 100% mutation coverage vs 17.6% for structure-dependent tools — predicting resistance with no crystal structure required.' The problem/solution field (limited to a few sentences) should open with the oncology and AMR stakes, pivot to ESM-2 delta-embeddings and the Platinum benchmark AUROC, and close with the Servier pilot as the near-term commercial anchor. The €100–400k ask maps precisely to Heartfelt's check range and should be framed explicitly as runway to fine-tune ESM-2 on SKEMPI (3K mutations), hit AUROC ≥0.70, and execute the Servier pilot — a textbook 0-to-1 inflection that is the stated purpose of Heartfelt's fund. Location must read Île-de-France / Paris, the deck must be VC-tailored (not the SEMIA grant narrative), and if possible a warm intro from a Kiin Bio or TriasBio founder should precede or accompany the resubmission.